You are on page 1of 8

Migraine - Pipeline Review, H2 2015 Is Released

Migraine - Pipeline Review, H2 2015 Summary Global Markets Direct s, Migraine - Pipeline Review, H2
2015, provides an overview of the Migraines therapeutic pipeline. This report provides comprehensive
information on the therapeutic development for Migraine, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic development for Migraine and special
features on late-stage and discontinued projects. Global Markets Directs report features investigational
drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets
Directs team. Drug profiles/records featured in the report undergoes periodic updation following a
stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline
products under drug profile section which includes, product description, MoA and R&D brief, licensing
and collaboration details & other developmental activities - The report reviews key players involved in
the therapeutics development for Migraine and enlists all their major and minor projects - The report
summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products
under development by companies and universities/research institutes based on information derived
from company and industry-specific sources - Pipeline products coverage based on various stages of
development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment
of monotherapy and combination therapy pipeline projects - Coverage of the Migraine pipeline on the
basis of target, MoA, route of administration and molecule type - Latest news and deals relating related
to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Migraine Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of
Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand business potential and
scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline.

with TOC @


To Get Sample Copy of Report visit @

Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
Migraine Overview 10
Therapeutics Development 11
Pipeline Products for Migraine - Overview 11
Pipeline Products for Migraine - Comparative Analysis 12
Migraine - Therapeutics under Development by Companies 13
Migraine - Therapeutics under Investigation by Universities/Institutes 17
Migraine - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Migraine - Products under Development by Companies 22
Migraine - Products under Investigation by Universities/Institutes 27
Migraine - Companies Involved in Therapeutics Development 28
Ache Laboratorios Farmaceuticos S/A 28
Acorda Therapeutics, Inc. 29
Afferent Pharmaceuticals, Inc. 30
Alder Biopharmaceuticals Inc. 31
Allergan Plc 32
Amgen Inc. 33

Astellas Pharma Inc. 34

BioDelivery Sciences International, Inc. 35
Biofrontera AG 36
Charleston Laboratories, Inc. 37
CoLucid Pharmaceuticals, Inc. 38
Corium International, Inc. 39
D-Pharm Ltd. 40
Eli Lilly and Company 41
iCeutica, Inc. 42
Impel NeuroPharma, Inc. 43
Mallinckrodt Plc 44
Medestea Research & Production S.p.A. 45
Merck & Co., Inc. 46
Monosol Rx, LLC 47
NAL Pharmaceuticals Ltd. 48
Nektar Therapeutics 49
Noxxon Pharma AG 50
Otsuka Holdings Co., Ltd. 51
Pantarhei Bioscience BV 52
Pivot Pharmaceuticals Inc 53
Pozen, Inc. 54
Promius Pharma, LLC 55
RedHill Biopharma Ltd. 56
Revance Therapeutics, Inc. 57
Shin Nippon Biomedical Laboratories, Ltd. 58
Suda Ltd 59
Teva Pharmaceutical Industries Limited 60

TheraJect, Inc. 61
Trevena, Inc. 62
Trigemina, Inc. 63
Vertex Pharmaceuticals Incorporated 64
Zosano Pharma Corporation 65
Migraine - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Target 68
Assessment by Mechanism of Action 72
Assessment by Route of Administration 75
Assessment by Molecule Type 77
Drug Profiles 79
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 79
(naproxen sodium + naratriptan hydrochloride) - Drug Profile 81
(sumatriptan succinate + naproxen sodium) - Drug Profile 82
(sumatriptan succinate + promethazine hydrochloride) - Drug Profile 84
AA-71 - Drug Profile 85
AF-130 - Drug Profile 86
AF-220 - Drug Profile 87
ALD-403 - Drug Profile 88
AMG-301 - Drug Profile 90
AMG-334 - Drug Profile 91
AST-003 - Drug Profile 92
BEMA Triptan - Drug Profile 93
BF-1 - Drug Profile 94

C-012 - Drug Profile 95

cloxyquin - Drug Profile 96
corticotropin - Drug Profile 97
daxibotulinumtoxin A - Drug Profile 99
Deina - Drug Profile 101
DFN-02 - Drug Profile 102
DFN-10 - Drug Profile 103
DFN-11 - Drug Profile 104
DFN-14 - Drug Profile 105
DFN-15 - Drug Profile 106
DFN-19 - Drug Profile 107
dihydroergotamine mesylate - Drug Profile 108
dihydroergotamine mesylate - Drug Profile 110
dihydroergotamine mesylate - Drug Profile 111
DORA-12 - Drug Profile 112
DP-VPA - Drug Profile 113
estetrol - Drug Profile 115
histamine dihydrochloride - Drug Profile 117
ICE-1209 - Drug Profile 118
ICE-1210 - Drug Profile 119
ICE-1211 - Drug Profile 120
ketoprofen - Drug Profile 121
lasmiditan succinate - Drug Profile 123
LY-2951742 - Drug Profile 125
MK-8031 - Drug Profile 127
NKTR-192 - Drug Profile 128
NOXL-41 - Drug Profile 129

NXN-188 - Drug Profile 130

NXN-462 - Drug Profile 131
oxytocin - Drug Profile 132
P-003 - Drug Profile 133
picotamide - Drug Profile 134
propofol hemisuccinate - Drug Profile 135
Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 136
rizatriptan benzoate - Drug Profile 137
rizatriptan benzoate - Drug Profile 139
rizatriptan benzoate - Drug Profile 140
Small Molecule to Antagonize CGRP for Migraine - Drug Profile 141
Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 142
Small Molecule to Antagonize Kappa Opioid Receptor for Migraine - Drug Profile 143
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 144
Small Molecule to Inhibit nNOS/NET for Migraine and Neuropathic Pain - Drug Profile 145
Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 146
Small Molecules to Antagonize 5-HT2B for Migraine - Drug Profile 147
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 148
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 149
Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile 150
SST-8055 - Drug Profile 151
sumatriptan succinate - Drug Profile 152
sumatriptan succinate - Drug Profile 153
sumatriptan succinate - Drug Profile 155
sumatriptan succinate - Drug Profile 157
TEV-48125 - Drug Profile 158

Tribarcina - Drug Profile 160

TRV-250 - Drug Profile 161
ubrogepant - Drug Profile 163
zolmitriptan - Drug Profile 164
zolmitriptan - Drug Profile 165
zolmitriptan - Drug Profile 166
zolmitriptan - Drug Profile 167
Migraine - Recent Pipeline Updates 168
Migraine - Dormant Projects 195
Migraine - Discontinued Products 201
Migraine - Product Development Milestones 202
Featured News & Press Releases 202
Appendix 211
Methodology 211
Coverage 211
Secondary Research 211
Primary Research 211
Expert Panel Validation 211
Contact Us 211
Disclaimer 212

Read More
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and

discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
iData Insights
Tel: 1-866-237-2965
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects